In conclusion, we developed a novel peptide biosensor‐based nano‐probe and succeeded in using it to monitor the cancer‐associated CDK4 kinase activity and the therapeutic response to the CDK4/6 inhibitor in living cells and in vivo. This evidence concerns the gene CDK4 and cancer.